值得注意的是，科笛近期发布公告，CU-30101(局部外用利多卡因丁卡因乳膏剂)药品上市许可申请已获得国家药监局受理，预计进度为全市场同类产品中最快。方正证券指出，当前麻膏产品合规占比低，预计获批后有望占领外用麻膏合规市场新蓝海；公司短期商业化驱动强势高增叠加长期研发端高壁垒领先，存在多维度超预期可能性。Shares of Kedi-B (02487) rose more than 5% in the afternoon. As of the time of publication, it was up 3.97% to HK$12.06, with a turnover of 11.6842 million Hong Kong dollars.
According to the Zhitong Finance APP, shares of Kedi-B (02487) rose more than 5% in the afternoon. As of the time of publication, it was up 3.97% to HK$12.06, with a turnover of 11.6842 million Hong Kong dollars.
In terms of news, Kedi released an announcement that the Phase III clinical trial results of its androgenetic alopecia treatment product CU-40102 (external finasteride spray) have been accepted and presented in the form of an electronic poster at the 8th Hair Congress of the Chinese Medical Association. It is reported that CU-40102 is the world's first and only approved external finasteride product for the treatment of androgenetic alopecia, as well as the first external finasteride product to have its New Drug Application accepted by the China National Medical Products Administration.
It is worth noting that Kedi recently announced that the application for the marketing authorization of CU-30101 (topical lidocaine and prilocaine cream) has been accepted by the National Medical Products Administration and is expected to have the fastest progress among similar products in the entire market. Fangzheng Securities pointed out that the compliance rate of current mustard plaster products is low, and it is expected that once approved, it will occupy a new blue ocean market for compliant topical mustard plaster; the company's short-term commercial drive is strong, with strong long-term research and development barriers, and there are multiple dimensions of exceeding expectations.
